FDA Expands Age Range for Bacterial Meningitis Vaccine
The US Food and Drug Administration (FDA) has expanded the approved age range for Menactra, a bacterial meningitis vaccine, to include children ages 2 to 10 years.
The US Food and Drug Administration (FDA) has expanded the approved age range for Menactra, a bacterial meningitis vaccine, to include children ages 2 to 10 years.
First approved by FDA in January 2005, Menactra was initially recommended for people ages 11 to 55 years. Previously, Menomune was the only meningococcal vaccine available in the US for use in children ages 2 years and older. Menactra and Menomune are both manufactured by sanofi pasteur Inc., (Swiftwater, PA) and both offer protection against four groups of Neisseria meningitidis, the bacterium that can cause meningitis.
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices currently recommends meningococcal vaccination for children ages 2 to 10 years who are at increased risk of developing meningococcal disease. Vaccination also is used to control outbreaks of bacterial meningitis.
FDA and CDC will continue to monitor the safety of Menactra through their jointly administered vaccine adverse event reporting system.
Meningitis is an inflammation of the lining that surrounds the spinal cord and brain. It can result in death or permanent injury to the brain and nervous system. In the US, about 2,600 people become ill from bacterial meningitis annually. About 10 percent die from the infection and another 15 percent suffer brain damage or limb amputation.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
